Non-Alcoholic Steatohepatitis (NASH) Market Report 2026

The non-alcoholic steatohepatitis (nash) market size has grown exponentially in recent years. It will grow from $6.06 billion in 2025 to $8.04 billion in 2026 at a compound annual growth rate (CAGR) of 32.7%. The growth in the historic period can be attributed to limited awareness about nash, lack of effective treatment options, reliance on lifestyle modifications, high prevalence of metabolic disorders, fragmented market landscape.

The non-alcoholic steatohepatitis (nash) market size is expected to see exponential growth in the next few years. It will grow to $24.32 billion in 2030 at a compound annual growth rate (CAGR) of 31.9%. The growth in the forecast period can be attributed to advancements in targeted therapies, increased healthcare expenditure, growing adoption of non-invasive diagnostics, expansion of pharmaceutical pipelines, rising collaborations for r&d. Major trends in the forecast period include rising prevalence of obesity and type 2 diabetes, development of non-invasive diagnostic tools, increasing research in liver fibrosis therapies, growth in personalized and targeted drug treatments, expansion of hospital and retail pharmacy networks.

The rising prevalence of obesity is driving demand in the non-alcoholic steatohepatitis (NASH) market. Obesity is defined as an abnormal or excessive accumulation of body fat that poses a health risk and is higher than what is considered healthy or normal for a person of a given height. As non-alcoholic fatty liver disease becomes increasingly common due to the obesity epidemic, NASH is projected to become a leading cause of severe liver disease in the coming decades, fueling demand for NASH treatments and related drugs. For example, in May 2025, according to the UK Government Digital Service, during 2023-2024, the prevalence of overweight (including obesity) in adults was higher among men (69.7%) than women (59.2%), while adult obesity rates were higher among women (26.9%) than men (26.2%). This trend underscores that rising obesity rates are expected to drive growth in the NASH market.

Key companies in the NASH market are focusing on the development of thyroid hormone receptor-beta (THR-beta) agonists to enhance liver metabolism, reduce liver fat accumulation, and improve liver function. THR-beta agonists are compounds that selectively activate the thyroid hormone receptor-beta subtype, which plays a crucial role in regulating metabolism, growth, and development. For instance, in March 2024, the U.S. Food and Drug Administration approved Rezdiffra (resmetirom), a THR-beta agonist, as the first treatment for adults with noncirrhotic NASH and moderate to advanced liver fibrosis. By selectively targeting the THR-beta receptor, Rezdiffra regulates lipid metabolism, reducing intrahepatic triglycerides and overall liver fat accumulation.

In April 2024, Novo Nordisk A/S, a Denmark-based global healthcare company, entered research collaborations with Omega Therapeutics and Cellarity to explore novel treatments for cardiometabolic diseases. The partnerships aim to accelerate the discovery and development of innovative therapies targeting metabolic and cardiovascular conditions, improving patient outcomes while driving growth and innovation in the cardiometabolic disease sector. Omega Therapeutics is a US-based biotechnology company specializing in gene control therapeutics, and Cellarity is a US-based biotech firm focused on cell reprogramming-based drug discovery.

Major companies operating in the non-alcoholic steatohepatitis (nash) market are NGM Biopharmaceuticals Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline plc., F. Hoffmann-La Roche AG, The Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Genfit SA, Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Blade Therapeutics Inc., Galmed Pharmaceuticals Inc., Immuron Limited, Terns Pharmaceuticals Inc., Tobira Therapeutics Inc., Arena Pharmaceuticals Inc., Galectin Therapeutics Inc., Viking Therapeutics, Madrigal Pharmaceuticals Inc., Cirius Therapeutics, Akero Therapeutics Inc., Echosens.

North America was the largest region in the non alcoholic steatohepatitis (NASH) market share in 2025. The regions covered in the non-alcoholic steatohepatitis (nash) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the non-alcoholic steatohepatitis (nash) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the non-alcoholic steatohepatitis (NASH) market by affecting the import of active pharmaceutical ingredients (APIs) and advanced diagnostic equipment, leading to increased production costs. The impact is most significant on pharmaceutical formulations and diagnostic devices, especially in regions like North America and Europe that rely on global supply chains. While costs have increased, some domestic manufacturers benefit from tariffs by gaining a competitive advantage and encouraging local production of APIs and NASH-related therapies. Overall, tariffs are reshaping sourcing strategies and encouraging innovation to optimize cost-efficiency.

The non-alcoholic steatohepatitis (nash) market research report is one of a series of new reports that provides non-alcoholic steatohepatitis (nash) market statistics, including non-alcoholic steatohepatitis (nash) industry global market size, regional shares, competitors with a non-alcoholic steatohepatitis (nash) market share, detailed non-alcoholic steatohepatitis (nash) market segments, market trends and opportunities, and any further data you may need to thrive in the non-alcoholic steatohepatitis (nash) industry. This non-alcoholic steatohepatitis (nash) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Non-alcoholic steatohepatitis (NASH) is a severe form of fatty liver disease marked by liver inflammation, which can progress to cirrhosis and liver failure.

The main types of NASH treatments are solid and liquid forms. Solid forms are typically produced as crystalline solids and sold as tablets for oral use, due to their high purity and stability. Key products include vitamin E, pioglitazone, Ocaliva, elafibranor, selonsertib, cenicriviroc, and others, which are used to address conditions such as hypertension, heart disease, high blood lipids, type 2 diabetes, and obesity. These treatments are available through hospital pharmacies, retail pharmacies, and online providers, and are administered via oral and parenteral routes.

The non-alcoholic steatohepatitis (NASH) market consists of sales of drugs that are used for the treatment of non-alcoholic fatty liver diseases. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.